三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
用于CML治疗的TKIs获批上市和医保目录纳入情况
用于CML治疗的TKIs获批上市和医保目录纳入情况
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:278KB
图片尺寸:2281*1361
同报告图片
/
4
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
所属报告:
翰森制药-港股公司研究报告-创新能力持续兑现的制药企业兼具业绩稳健与创新弹性-250606(69页).pdf
打包全文图表
相关数据
慢性髓系白血病(CML)临床诊疗流程
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
收藏
行业数据
2025-08-25
原图定位
查看详情
CML致病机制与奥雷巴替尼(HQP1351)作用通路示意
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
收藏
行业数据
2025-02-06
原图定位
查看详情
慢性髓性白血病(CML)慢性期(CP)患者治疗方案
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
收藏
行业数据
2024-12-30
原图定位
查看详情
针对BCR-ABL融合蛋白的TKI类药物目前是治疗CML的首选
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
收藏
行业数据
2024-12-26
原图定位
查看详情
预计全球与中国CML新发患者逐年缓慢增长(千人)
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
收藏
行业数据
2024-12-26
原图定位
查看详情
治疗BCR-ABLT315I突变CML疗及安全对比
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
收藏
行业数据
2024-08-08
原图定位
查看详情
舒沃替尼单药对三代EGFR-TKIs耐药患者显示出疗效信号
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
收藏
行业数据
2023-05-18
原图定位
查看详情
奥雷巴替尼治疗CML-CP美国数据
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
收藏
行业数据
2023-05-08
原图定位
查看详情
2015-2030(预期)EGFR-TKIs药物全球市场规模
fCDlubTku70gfCDluILlnLrop4TmqKHvvIjljYHkur/nvo7lhYPvvIkgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLXwKfCAyMDE1IHwgMy4zICAgICAgICAgICAgICB8CnwgMjAxNiB8IDMuOCAgICAgICAgICAgICAgfAp8IDIwMTcgfCA0LjMgICAgICAgICAgICAgIHwKfCAyMDE4IHwgNC45ICAgICAgICAgICAgICB8CnwgMjAxOSB8IDUuMyAgICAgICAgICAgICAgfAp8IDIwMjBFfCA2LjAgICAgICAgICAgICAgIHwKfCAyMDIxRXwgNy4xICAgICAgICAgICAgICB8CnwgMjAyMkV8IDguNyAgICAgICAgICAgICAgfAp8IDIwMjNFfCAxMC40ICAgICAgICAgICAgIHwKfCAyMDI0RXwgMTIuMyAgICAgICAgICAgICB8CnwgMjAyNUV8IDE0LjEgICAgICAgICAgICAgfAp8IDIwMjZFfCAxNi4xICAgICAgICAgICAgIHwKfCAyMDI3RXwgMTguMCAgICAgICAgICAgICB8CnwgMjAyOEV8IDE5LjkgICAgICAgICAgICAgfAp8IDIwMjlFfCAyMS42ICAgICAgICAgICAgIHwKfCAyMDMwRXwgMjMuMiAgICAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJrlvJfoi6Xmlq/nibnmspnliKnmlofvvIjovazlvJXoh6rov6rlk7LljLvoja/mi5vogqHor7TmmI7kuabvvIzlkKvpooTmtYvvvInvvIzkuK3kv6Hor4HliLjnoJTnqbbpg6g=
收藏
行业数据
2022-12-28
原图定位
查看详情
耐药CML(慢性髓系白血病)新发病例规模(万例)
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
收藏
行业数据
2022-11-18
原图定位
查看详情
国内外主要在研第三代BCR-ABL抑制剂在T315I突变CML治疗中的
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
收藏
行业数据
2022-08-02
原图定位
查看详情
国内外主要在研第三代BCR-ABL抑制剂在T315I突变CML治疗中的
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
收藏
行业数据
2022-08-01
原图定位
查看详情
全球EGFR-TKIs药物市场规模,2015-2030E
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
收藏
行业数据
2021-12-08
原图定位
查看详情
中国EGFR-TKIs药物市场规模,2015-2030E
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
收藏
行业数据
2021-12-08
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
目前全球已获批的 BCR-ABL TKI 一共有九种,其中主要的药物有第一代伊马替尼;达沙替尼、尼洛替尼、博苏替尼、氟马替尼四款二代 BCR-ABL TKI 药物和泊那替尼、奥雷巴替尼两款第三代 BCR-ABL TKI。国内竞争格局已形成,包括六款已获批上市的药物:奥雷巴替尼、氟马替尼、尼洛替尼、达沙替尼和伊马替尼。其中伊马替尼是为一代 TKI,氟马替尼、尼洛替尼、达沙替尼为第二代 TKI,泊那替尼和奥雷巴替尼为第三代 TKI。 氟马替尼是公司自主研发的第二代 TKI 药物,用于治疗 Ph 染色体阳性的 CML-CP 成人患者,2019年获批上市,目前已纳入国家医保。
行业数据
原图定位
当前图表所属:
翰森制药-港股公司研究报告-创新能力持续兑现的制药企业兼具业绩稳健与创新弹性-250606(69页).pdf
三代EGFRTKI联用EGFR/C-MET双特异性抗体关于EGFR敏感突变1L治疗适应症的试验进展
三代EGFRTKI药物获批和医保目录纳入情况
HS-20117相关临床试验进度
TYK2药物竞争格局
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》